199TiP A first-in-human phase I study of IPH5301, an anti-CD73 monoclonal antibody, alone or in combination with chemotherapy and trastuzumab, in patients with advanced solid tumors (CHANCES). (December 2022) - Gonçalves, A.; Vicier, C.; Guerin, M.; Pignon, J.; Chanez, B.; Provansal Gross, M.; Penel, N.; Kotecki, N.; Marie, D.B.; Boyer Chammard, A.; Paturel, C.L.; André, P.; et al.